7

# Translation

## PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference M/40226-PCT	FOR FURTHER ACTION	R FURTHER ACTION SeeNotificationofTransmittalofInternational Prelimina Examination Report (Form PCT/IPEA/416)					
International application No. PCT/EP00/07807	International filing date (day/m 10 August 2000 (10.1		Priority date (day/month/year) 11 August 1999 (11.08.99)				
International Patent Classification (IPC) or national classification and IPC C12N 15/53, 15/82, 9/02, 1/21, A01H 5/00, C07D 311/72, C12P 17/06							
Applicant SUNGENE GMBH & CO. KGAA							
<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> <li>This REPORT consists of a total of 5 sheets, including this cover sheet.</li> </ol>							
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
These annexes consist of a total		· · · · · · · · · · · · · · · · · · ·					
3. This report contains indications relating	ing to the following items:						
Basis of the report							
II Priority							
III Non-establishment of	f opinion with regard to novelty,	inventive step	p and industrial applicability				
IV Lack of unity of inver	ntion						
V Reasoned statement u	under Article 35(2) with regard to tions supporting such statement	o novelty, inv	ventive step or industrial applicability;				
VI Certain documents cit	ted						
VII Certain defects in the	VII Certain defects in the international application						
VIII Certain observations on the international application							
Date of submission of the demand	Date of c	completion of	this report				
09 March 2001 (09.03.0			nuary 2002 (02.01.2002)				
Name and mailing address of the IPEA/EP	Authorize	ed officer					
Facsimile No.	Telephon	Telephone No.					

International application No.

#### PCT/EP00/07807

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

I. Basis	s of the re	enort	
		to the elements of the international application:*	
		to the elements of the international application:  emational application as originally filed	
X		scription:	
لاعا	pages		
	pages		, as originally filed
	pages	, filed with the letter	, filed with the demand er of
$\nabla$			ж от
ĽΥ	the clair pages	1 10	
	pages .	, as amended (to	, as originally filed
	pages	——————————————————————————————————————	ogether with any statement under Article 19, filed with the demand
	pages	, filed with the letter	
$\bowtie$	the draw		.,
الاستع	pages		as originally filed
	pages _	113-373	, as originally filed , filed with the demand
	pages	, filed with the letter	
×ι	the seaue	ence listing part of the description:	
الاستعا	pages _	**	as ariainally filed
	pages _		, as originally filed
	pages _	, filed with the letter	r of
		guage of publication of the international application (under Rule 48.3(b)). guage of the translation furnished for the purposes of international prelim).	minary examination (under Rule 55.2 and/
3. With prelim	regard to	<ol> <li>any nucleotide and/or amino acid sequence disclosed in the interaction was carried out on the basis of the sequence listing:</li> </ol>	nternational application, the international
$\boxtimes$	containe	ed in the international application in written form.	
	filed toge	gether with the international application in computer readable form.	
		ed subsequently to this Authority in written form.	
		ed subsequently to this Authority in computer readable form.	
	internatio	atement that the subsequently furnished written sequence listing does ional application as filed has been furnished.	
	The state	tement that the information recorded in computer readable form is identified.	ntical to the written sequence listing has
	The ame	endments have resulted in the cancellation of:	
ļ		he description, pages	
Ļ	Liho	he claims, Nos.	
L	1	he drawings, sheets/fig	
Т	his repor seyond th	ort has been established as if (some of) the amendments had not been made the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).*	de, since they have been considered to go
and 70.	1.17).	neets which have been furnished to the receiving Office in response to an in as "originally filed" and are not annexed to this report since they do	do not contain amendments (Rule 70.16
'Any rep	lacement	nt sheet containing such amendments must be referred to under item I and a	annexed to this report.

#### IMTERNATIONAL PREDMINARY EXAMINATION REPORT

mational application No.
PCT/EP 00/07807

Statement			
Novelty (N)	Claims	2, 6, 9	YES
	Claims	1, 3-5, 7, 8, 10-18	_ NO
Inventive step (IS)	Claims		YES
	Claims	1-18	_ NO
Industrial applicability (IA)	Claims	1-18	YES
	Claims		- NO

#### 2. Citations and explanations

- The subject matter of the first claim contains 3 alternative subjects:
  - a) expression cassette containing a nucleic acid sequence that codes for HPPD or a functional equivalent thereof;
  - b) expression cassette containing a nucleic acid sequence that is capable of inhibiting HGD;
  - c) expression cassette containing a) and b).

#### Novelty (PCT Article 33(2))

2. WO-A-99/04021 (D1) describes a nucleic acid that codes for an HPPD from barley, and tobacco plants that are transformed using a corresponding expression cassette (Example 7, page 27). The tobacco plants transformed with the constructs have a higher tocopherol concentration in comparison with non-transformed plants.

This part of the subject matter (see a) above) of Claims 1, 3 (see D1, page 1, second paragraph), 4, 5 ("functional equivalent"), 7-8 and 10-18 is therefore anticipated by D1 in a manner prejudicial to novelty.

- 3. Claims 2, 6 and 9, which are dependent on this part, are novel.
- 4. The subjects of Claim 1 designated b) and c) above and the claims dependent thereon are considered novel.

# Inventive step of alternatives b) and c) (PCT Article 33(3))

5. D1 is the closest prior art, the teaching of which is specified above. In comparison thereto, the present application proposes, in order to increase the tocopherol content of plants, to transform said plants using a construct that codes for a nucleic acid that is capable of inhibiting HGD activity, or using a construct(s) that codes for HPPD and a nucleic acid and is capable of inhibiting HGD activity.

The application therefore addresses the problem of preparing plants with an increased tocopherol content.

The application does not show whether the proposed alternatives can actually solve the problem (see Example 4). Consequently, an inventive step cannot be acknowledged for the above problem.

If it were possible to submit comparative results that show an increase in tocopherol content as a result of the specified constructs, then inventive step could be acknowledged, since none of the documents cited in the search report proposes suppressing maleylacetoacetate synthesis.

6. In the light of the data contained in the application, the **objective** technical problem addressed by the application is that of preparing transformed plants. Selecting from the variety of possible nucleic acids those that code for HPPD and HGD solves the problem in a non-inventive manner, since it is an arbitrary choice that does not result in a special technical effect. Consequently, an inventive step cannot be acknowledged on the basis of the objective technical problem.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

nternational application No.

PCT/EP00/07807

#### VI. Certain documents cited

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO00/08169	17 February 2000 (17.02.2000)	30 July 1999 (30.07.1999)	05 August 1998 (05.08.1998)
FR2 778 527	19 November 1999 (19.11.1999)	18 May 1998 (18.05.1998)	

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure Date of non-

Date of non-written disclosure (day/month/year)

Date of written disclosure referring to non-written disclosure (day/month/year)